ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free NEU Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neuren Pharmaceuticals alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Neuren Pharmaceuticals Stock (ASX:NEU)Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. NEU Stock News HeadlinesApril 3, 2024 | msn.comASX loses 1.3% on back of Wall Street decline, gold price hits new high and the world's richest people are getting richer — as it happenedApril 1, 2024 | finance.yahoo.comHere's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of InvestorsApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 26, 2024 | uk.finance.yahoo.com20 Biggest Health Care Companies in Australia, 2024March 18, 2024 | fool.com.auThe best ASX shares to invest $500 in right nowMarch 11, 2024 | fool.com.au$10k of savings? I'd buy these ASX 200 shares to grow my moneyMarch 3, 2024 | finance.yahoo.comNeuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their ModelsFebruary 29, 2024 | fool.com.auWhat's with the Neuren Pharmaceuticals share price today?April 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.February 28, 2024 | msn.comInflation remains at two-year low, Optus sacks extra 200 staff, Sony terminates 8pc of workforce, ASX finishes flat — as it happenedFebruary 28, 2024 | fool.com.auWhy is this ASX 200 pharmaceuticals stock crashing 15% today?February 16, 2024 | msn.comNeuren (NEU) Shares Plunge as Short Seller Targets Partner AcadiaFebruary 15, 2024 | fool.com.auThis ASX 200 healthcare share is diving 13% as short sellers take aimJanuary 18, 2024 | forbes.comStock Market Outlook In 2024January 15, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Clinuvel Pharmaceuticals Limited (CLVLF)January 12, 2024 | fool.com.au3 pharma shares outshining the ASX index todayJanuary 8, 2024 | fool.com.auThe Neuren Pharmaceuticals share price is up 100% in 3 months: Can it keep rising?January 6, 2024 | fool.com.auThe No. 1 ASX 200 shares of each market sector in 2023January 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Innovent Biologics (IVBXF), Telix Pharmaceuticals Ltd. (TLPPF)December 26, 2023 | finance.yahoo.comAn Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 44% UndervaluedDecember 22, 2023 | fool.com.auWhy Boss Energy, Lynas, Neuren, and Ora Banda shares are rising todayDecember 19, 2023 | au.investing.comNeuren Pharmaceuticals' shares surge on positive Phase 2 clinical trial resultsDecember 18, 2023 | fool.com.auGuess which ASX 200 stock was just upgraded and tipped to rise 20%+December 17, 2023 | fool.com.auWhy is this ASX 200 healthcare stock surging 32% on Monday?December 13, 2023 | finance.yahoo.comAustralia Shares Rise, Helped by Healthcare StocksDecember 10, 2023 | afr.comNew fund targets companies battered by market doubtsNovember 6, 2023 | morningstar.comNeuren Pharmaceuticals Ltd NEUSee More Headlines Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:NEU CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$1.20 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$157.08 million Net Margins67.72% Pretax MarginN/A Return on Equity127.30% Return on Assets85.52% Debt Debt-to-Equity RatioN/A Current Ratio5.78 Quick Ratio31.54 Sales & Book Value Annual Sales$231.94 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.61 per share Price / BookN/AMiscellaneous Outstanding Shares129,950,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.99 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jonathan Charles Pilcher A.C.A.ACA, B.Sc., BSc (Hons), F.C.A., CEO, MD & Executive DirectorMs. Lauren Frazer C.A.CFO & Company SecretaryMr. Lawrence Glass BA (Biology)Chief Science OfficerMr. Gerry ZhaoVice President of Corporate DevelopmentDr. Liza A. Squires M.D.Chief Medical OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJoseph(Joe) BasileBought 5,000 shares on 9/13/2023Total: $59,950.00 ($11.99/share)Trevor ScottSold 1,175,000 sharesTotal: $15.28 M ($13.00/share) NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) announced its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 127.30% and a net margin of 67.72%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Afterpay (APT) and Alkane Resources (ALK). This page (ASX:NEU) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
